Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 0118 • ACR Convergence 2022
Sex-Based Variations in Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions
Cheryl Barnabe¹, Patrick McLane², Nadia Luca¹, Katie Lin¹, Kelsey Chomistek¹, Meghan Elliott¹, Shanon McQuitty³, Eileen Davidson³, Clare Hildebrandt⁴, Steven Katz², Brian Holroyd² and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Patient and Family Advisors, Alberta Health Services, Calgary, AB, Canada
Background/Purpose: High quality ambulatory care provision should mitigate avoidable emergency department (ED) visits by persons with inflammatory arthritis (IA) conditions and address the unique realities…
Abstract Number: 0861 • ACR Convergence 2022
Incidence of Juvenile Idiopathic Arthritis During the COVID-19 Pandemic: An Analysis of National United States Administrative Claims Data
Daniel Horton¹, Amanda Neikirk², Yiling Yang², Cecilia Huang³, Stephen Crystal⁴, amy davidow⁵, Kevin Haynes⁶, Tobias Gerhard⁷, Carlos Rose⁸, Brian Strom⁹ and Lauren Parlett², ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²HealthCore, Wilmington, DE, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, ⁴Rutgers Center for Health Services Research, New Brunswick, NJ, ⁵New York University, New York, NY, ⁶Johnson & Johnson, Titusville, NJ, ⁷Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, ⁸Nemours, Chadds Ford, PA, ⁹Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: Limited information exists on how rates of diagnosis of rheumatic diseases have changed during the COVID-19 pandemic. We compared rates of JIA diagnosis before…
Abstract Number: 1298 • ACR Convergence 2022
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis
Catherine Bingham¹, Julia Harris², Sheetal Vora³, Mileka Gilbert⁴, Cagri Yildirim-Toruner⁵, Kerry Ferraro⁶, Tingting Qiu⁷, Jon Burnham⁸, Michelle Batthish⁹, Beth Gottlieb¹⁰, Daniel Lovell⁷, Ronald Laxer¹¹, Tzielan Lee¹², Danielle Bullock¹³, Charles H Spencer¹⁴, Jennifer Weiss¹⁵, Melissa Hazen¹⁶, Edward Oberle¹⁷, Melissa Mannion¹⁸, Nancy Pan¹⁹, Michael Shishov²⁰, Danielle Fair²¹, Mary Toth²², Kendra Wiegand⁷ and Esi Morgan²³, ¹Penn State Children's Hospital, Hershey, PA, ²Children's Mercy Kansas City, Overland Park, KS, ³Atrium Health Levine Children's, Charlotte, NC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Texas Children's Hospital/ Baylor College of Medicine, Houston, TX, ⁶Pediatric Rheumatology Care and Outcomes Improvement Network, Philadelphia, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹McMaster University, Hamilton, ON, Canada, ¹⁰Cohen Children's Medical Center, Lake Success, NY, ¹¹Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹²Stanford University School of Medicine, Palo Alto, CA, ¹³University of Minnesota, Minneapolis, MN, ¹⁴Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, MS, ¹⁵Hackensack University Medical Center, Hackensack, NJ, ¹⁶Boston Children's Hospital, Boston, MA, ¹⁷Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ¹⁸University of Alabama at Birmingham, Birmingham, AL, ¹⁹Hospital for Special Surgery, New York, NY, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ²²Nemours Foundation, Orlando, FL, ²³Seattle Children's Hospital, Seattle, WA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a Learning Health Network designed to improve outcomes of care for children with juvenile idiopathic…
Abstract Number: 0119 • ACR Convergence 2022
Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions Varies by Geographic Location of Residence
Cheryl Barnabe¹, Patrick McLane², Nadia Luca¹, Kelsey Chomistek¹, Meghan Elliott¹, Shanon McQuitty³, Steven Katz², Eileen Davidson³, Clare Hildebrandt⁴, Katie Lin¹, Brian Holroyd² and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Patient and Family Advisors, Alberta Health Services, Calgary, AB, Canada
Background/Purpose: Rheumatology services in Canada are largely restricted to urban centres, resulting in significant access difficulties for residents of rural and remote locations. As a…
Abstract Number: 0862 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: An Analysis of National United States Administrative Claims Data
Daniel Horton¹, Yiling Yang², Amanda Neikirk², Cecilia Huang³, Stephen Crystal⁴, amy davidow⁵, Kevin Haynes⁶, Tobias Gerhard⁷, Carlos Rose⁸, Brian Strom⁹ and Lauren Parlett², ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²HealthCore, Wilmington, DE, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, ⁴Rutgers Center for Health Services Research, New Brunswick, NJ, ⁵New York University, New York, NY, ⁶Johnson & Johnson, Titusville, NJ, ⁷Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, ⁸Nemours, Chadds Ford, PA, ⁹Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: Limited information exists on COVID-19 pandemic-related changes in the management of rheumatic diseases in adults or children, besides what patients and families have reported.…
Abstract Number: 1299 • ACR Convergence 2022
Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children
Jo-Anne Marcuz¹, Brian Feldman², Y. Ingrid Goh³, Niina Kim⁴, Piya Lahiry⁵, Deborah Levy², Elizaveta Limenis⁶, Jeanine McColl⁷, Christine O'Brien⁸, Susan Paetkau⁴, Shirley Tse², Kristi Whitney⁸ and Ronald Laxer², ¹Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children; Department of Pediatrics, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in children with significant morbidity that extends into adulthood. Despite advances in effective…
Abstract Number: 0137 • ACR Convergence 2022
Polyarticular Arthritis and Osteolysis Caused by Mutations in the ASAH1 Gene: Farber Disease Clinical Presentations in the First-ever Natural History Study
Alexander Solyom¹, Kathleen Crosby², Nils Confer² and Jaime Lopez Valdez³, ¹Aceragen, Basel, Switzerland, ²Aceragen, Durham, NC, ³Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico
Background/Purpose: Farber disease is frequently misdiagnosed as polyarticular juvenile idiopathic arthritis or seronegative rheumatoid arthritis which leads to a delay in diagnosis for many patients.…
Abstract Number: 0863 • ACR Convergence 2022
Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study
Karen James¹, George Tomlinson², Tim Beukelman³, Laura Schanberg⁴, Anne Dennos⁵, VIncent Del Gaizo⁶, Marian Jelinek⁷, Erin Pfeifer⁸, Shalini Mohan⁹ and Yukiko Kimura¹⁰, ¹University of Utah, Salt Lake City, UT, ²University of Toronto, Toronto, ON, Canada, ³Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Childhood Arthritis and Rheumatology Research Alliance (CARRA), Durham, NC, ⁷Childhood Arthritis and Rheumatology Research Alliance (CARRA), Duke, ⁸Genentech, Englewood, NJ, ⁹Genentech, San Diego, ¹⁰Hackensack Meridian Health, New York, NY

Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a systemic autoinflammatory disease characterized by high fevers, rash and arthritis. Current treatment regimens often involve biologic (anti-IL-1…
Abstract Number: 1418 • ACR Convergence 2022
Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry
Colleen Correll¹, Scott Stryker², David Collier³, Anne Dennos⁴, Stephen Balevic⁵, Thomas Phillips⁵ and Tim Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Amgen Inc., San Francisco, CA, ³Amgen Inc., Simi Valley, CA, ⁴Duke University, Durham, NC, ⁵Duke Clinical Research Institute, Durham, NC, ⁶Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL
Background/Purpose: Juvenile psoriatic arthritis (JPsA) constitutes ~5% of juvenile idiopathic arthritis (JIA). Several therapeutics are available for JPsA; however, given the low JPsA incidence, important…
Abstract Number: 0562 • ACR Convergence 2022
Large-Scale Targeted Sequencing Study Links Systemic Juvenile Idiopathic Arthritis with Rare Variants of MEFV, LYST, STXBP2, UNC13D
Mariana Correia Marques¹, Danielle Rubin², Emily Shuldiner², Elizabeth Schmitz², Elizabeth Baskin², Andrew Patt³, Alexei Grom⁴, Dirk Foell⁵, Marco Gattorno⁶, John Bohnsack⁷, Rae Yeung⁸, Sampath Prahalad⁹, Elizabeth Mellins¹⁰, Jordi Antón¹¹, Claudio Len¹², Sheila Oliveira¹³, Patricia Woo¹⁴, Seza Ozen¹⁵, INCHARGE Consortium¹⁶ and Michael Ombrello¹⁷, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases / Children`s National Hospital, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ³National Center for Advancing Translational Sciences, Bethesda, MD, ⁴Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵University Hospital Münster, Münster, Germany, ⁶Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁷University of Utah, Salt Lake City, UT, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁹Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁰Stanford University, Stanford, CA, ¹¹Pediatric Rheumatology Department. Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat, Spain, ¹²Universidade Federal de São Paulo, São Paulo, Brazil, ¹³Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁴University College London, London, United Kingdom, ¹⁵Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁶International Childhood Arthritis Genetics Consortium, Bethesda, MD, ¹⁷National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a genetically complex inflammatory condition. It can be marked by severe systemic inflammation that resembles the hereditary periodic…
Abstract Number: 0864 • ACR Convergence 2022
Baseline Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
Esraa Eloseily¹, Min-Lee Chang², MaryEllen Riordan³, Alan Russell⁴, Marc Natter², Yukiko Kimura⁵ and Grant Schulert⁶, ¹Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Boston Children's Hospital, Boston, MA, ³Hackensack Meridian Health, Hackensack, NJ, ⁴Duke Clinical Research Institute, Duke, NC, ⁵Hackensack Meridian Health, New York, NY, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life threatening clinical problem, and currently affects as many as 1…
Abstract Number: 1679 • ACR Convergence 2022
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, MaryEllen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Mei Sing Ong¹¹ and Marc Natter¹², ¹Hackensack Meridian Health, New York, NY, ²Janssen, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack Meridian Health, Hackensack, NJ, ⁷CARRA, Inc, Washington, DC, ⁸CARRA, Inc, New Orleans, LA, ⁹Children's Hospital of Philadelphia, Glen Mills, PA, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹¹Harvard Pilgrim Institute, Boston, MA, ¹²Boston Children's Hospital, Boston, MA
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: 0729 • ACR Convergence 2022
Understanding the Practice and Process of Patient Reported Outcome Measures Collection in North American Pediatric Rheumatology Clinics: A Survey of the Pediatric Rheumatology-Care and Outcomes Improvement Network
Y. Ingrid Goh¹, Esi Morgan², Meghan Ryan³, Beth Gottlieb⁴ and Nancy Pan⁵, ¹Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, ²Seattle Children's Hospital, Seattle, WA, ³University of Minnesota, Vadnais Heights, MN, ⁴Cohen Children's Medical Center, Lake Success, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Patients/proxies (Pts) complete patient reported outcome measures (PROMs) to inform their healthcare team about their health status. PROMs completed by Pts prior to their…
Abstract Number: 0867 • ACR Convergence 2022
Regulatory Haplotype of CXCR4 Is Associated with sJIA and Corelates with Enhanced Neutrophil and CD14+ Monocyte Migration
Hiroto Nakano¹, Emily Shuldiner², Anne Hinks³, Marc Sudman⁴, Elaine Remmers⁵, Colleen Satorius⁶, Elizabeth Schmitz¹, Victoria Arthur⁷, Patricia Woo⁸, Alexei Grom⁹, Dirk Foell¹⁰, John Bohnsack¹¹, Marco Gattorno¹², Seza Ozen¹³, Sampath Prahalad¹⁴, Rae Yeung¹⁵, Elizabeth Mellins², Sheila Oliveira¹⁶, Jordi Antón¹⁷, Claudio Len¹⁸, Carol Lake¹⁹, Ly-Lan Bergeron²⁰, Michelle Millwood²¹, Estefania de los santos²¹, Mariana Correia Marques²², Juvenile Arthritis Consortium for the Immunochip²³, The Genomic Ascertainment Cohort Investigators²⁴, INCHARGE Consortium²⁵, Carl Langefeld²⁶, Susan Thompson²⁷, Wendy Thomson²⁸ and Michael Ombrello¹, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Stanford University, Stanford, CA, ³The University of Manchester, Manchester, United Kingdom, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵National Human Genome Research Institute, Bethesda, MD, ⁶NHGRI, NIH, Bethesda, MD, ⁷Boston Children's Hospital, Boston, MA, ⁸University College London, London, United Kingdom, ⁹Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰University Hospital Münster, Münster, Germany, ¹¹University of Utah, Salt Lake City, UT, ¹²Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹³Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁴Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁵The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ¹⁶Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁷Pediatric Rheumatology Department. Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat, Spain, ¹⁸Universidade Federal de São Paulo, São Paulo, Brazil, ¹⁹NIH, Gaithersburg, MD, ²⁰NIH/NIAMS, Vienna, VA, ²¹NIAMS, NIH, Bethesda, MD, ²²National Institute of Arthritis and Musculoskeletal and Skin Diseases / Children`s National Hospital, Bethesda, MD, ²³Juvenile Arthritis Consortium for the Immunochip, Bethesda, MD, ²⁴The Genomic Ascertainment Cohort Investigators, Bethesda, MD, ²⁵International Childhood Arthritis Genetics Consortium, Bethesda, MD, ²⁶Wake Forest School of Medicine, Winston Salem, NC, ²⁷Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, ²⁸Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare inflammatory disease that causes spiking fever, skin rash, chronic arthritis, and inflammation of the heart and…
Abstract Number: 1934 • ACR Convergence 2022
Transition Readiness Before versus After Adolescents with Rheumatic Disease Transition to Adult Care
Christina Ma¹, Alessana Carmona², Habeba Talaat², Julie Herrington³, Tania Cellucci⁴, Stephanie Garner², Mark Matsos², KAREN BEATTIE² and Michelle Batthish², ¹McMaster University, Canada, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³ACPAC, Hamilton, ON, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased disease activity and morbidity for patients with rheumatic disease. Consequently, there has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].